You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBethanidine
Accession NumberDB00217  (APRD00825)
TypeSmall Molecule
GroupsApproved
DescriptionA guanidinium antihypertensive agent that acts by blocking adrenergic transmission.
Structure
Thumb
Synonyms
Betanidina
Betanidine
Betanidinum
N,N'-dimethyl-N''-(phenylmethyl)-guanidine
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EsbatalNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Bethanidine sulfate
114-85-2
Thumb
  • InChI Key: YTIJUXVIZLYQTB-UHFFFAOYSA-N
  • Monoisotopic Mass: 452.220574232
  • Average Mass: 452.571
DBSALT000194
Categories
UNIIW8S3YM7AUU
CAS number55-73-2
WeightAverage: 177.2462
Monoisotopic: 177.126597495
Chemical FormulaC10H15N3
InChI KeyInChIKey=NIVZHWNOUVJHKV-UHFFFAOYSA-N
InChI
InChI=1S/C10H15N3/c1-11-10(12-2)13-8-9-6-4-3-5-7-9/h3-7H,8H2,1-2H3,(H2,11,12,13)
IUPAC Name
(E)-3-benzyl-1,2-dimethylguanidine
SMILES
CN\C(NCC1=CC=CC=C1)=N/C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylmethylamines. These are compounds containing a phenylmethtylamine moiety, which consists of a phenyl group substituted by an methanamine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylmethylamines
Direct ParentPhenylmethylamines
Alternative Parents
Substituents
  • Phenylmethylamine
  • Benzylamine
  • Guanidine
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboximidamide
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Imine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of hypertension.
PharmacodynamicsBethanidine is a guanidinium antihypertensive agent that acts by blocking adrenergic transmission. The precise mode of action is not clear. Although bethanidine may produce adverse effects, they are beneficial in severe hypertension and produce fewer side effects than guanethidine.
Mechanism of actionBethanidine, a guanidine derivative, is a peripherally acting antiadrenergic agent which primarily acts as an alpha2a adrenergic agonist. Bethanidine effectively decreases blood pressure by suppressing renin secretion or interfering with function of the sympathetic nervous system.
Related Articles
AbsorptionAbsorbed rapidly in the gastrointestinal tract following oral administration.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life9 hours (range 7 to 11 hours)
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9713
Blood Brain Barrier+0.85
Caco-2 permeable+0.5072
P-glycoprotein substrateNon-substrate0.5681
P-glycoprotein inhibitor INon-inhibitor0.9217
P-glycoprotein inhibitor IINon-inhibitor0.6727
Renal organic cation transporterInhibitor0.5516
CYP450 2C9 substrateNon-substrate0.7952
CYP450 2D6 substrateNon-substrate0.5
CYP450 3A4 substrateNon-substrate0.7359
CYP450 1A2 substrateNon-inhibitor0.7802
CYP450 2C9 inhibitorNon-inhibitor0.9218
CYP450 2D6 inhibitorInhibitor0.5754
CYP450 2C19 inhibitorNon-inhibitor0.8195
CYP450 3A4 inhibitorNon-inhibitor0.8329
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9069
Ames testNon AMES toxic0.7985
CarcinogenicityNon-carcinogens0.886
BiodegradationNot ready biodegradable0.9161
Rat acute toxicity2.5507 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9126
hERG inhibition (predictor II)Non-inhibitor0.9191
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Ah robins co
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point196 °CPhysProp
logP0.49Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.58 mg/mLALOGPS
logP1.41ALOGPS
logP1.27ChemAxon
logS-2ALOGPS
pKa (Strongest Basic)12.41ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area36.42 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity54.5 m3·mol-1ChemAxon
Polarizability20.43 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Khashayar Karimian, Keshava Murthy, Darren Hall, “Methods of making ureas and guanidines, including terazosin, prazosin, doxazosin, tiodazosin, trimazosin, quinazosin, and bunazosin (exemplary of 2-substituted quinazoline compounds), and meobentine, and bethanidine and intermediates thereof.” U.S. Patent US5686612, issued November, 1990.

US5686612
General ReferencesNot Available
External Links
ATC CodesC02CC01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Bethanidine.
AcebutololBethanidine may increase the hypotensive activities of Acebutolol.
AlfuzosinAlfuzosin may increase the hypotensive activities of Bethanidine.
AliskirenBethanidine may increase the hypotensive activities of Aliskiren.
AlprenololBethanidine may increase the hypotensive activities of Alprenolol.
AmbrisentanBethanidine may increase the hypotensive activities of Ambrisentan.
AmifostineBethanidine may increase the hypotensive activities of Amifostine.
AmineptineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Amineptine.
AmitriptylineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Amitriptyline.
AmlodipineBethanidine may increase the hypotensive activities of Amlodipine.
ArotinololBethanidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.
AtenololBethanidine may increase the hypotensive activities of Atenolol.
BefunololBethanidine may increase the atrioventricular blocking (AV block) activities of Befunolol.
BenazeprilBethanidine may increase the hypotensive activities of Benazepril.
BendroflumethiazideBethanidine may increase the hypotensive activities of Bendroflumethiazide.
BenmoxinBenmoxin may increase the hypotensive activities of Bethanidine.
BepridilBethanidine may increase the hypotensive activities of Bepridil.
BetaxololBetaxolol may increase the hypotensive activities of Bethanidine.
BevantololBethanidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.
BimatoprostBethanidine may increase the hypotensive activities of Bimatoprost.
BisoprololBethanidine may increase the hypotensive activities of Bisoprolol.
BopindololBethanidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
BosentanBethanidine may increase the hypotensive activities of Bosentan.
BretyliumBethanidine may increase the hypotensive activities of Bretylium.
BrimonidineBethanidine may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Bethanidine.
BufuralolBethanidine may increase the atrioventricular blocking (AV block) activities of Bufuralol.
BupranololBethanidine may increase the hypotensive activities of Bupranolol.
CandesartanBethanidine may increase the hypotensive activities of Candesartan.
CandoxatrilBethanidine may increase the hypotensive activities of Candoxatril.
CaptoprilBethanidine may increase the hypotensive activities of Captopril.
CaroxazoneCaroxazone may increase the hypotensive activities of Bethanidine.
CarteololBethanidine may increase the hypotensive activities of Carteolol.
CarvedilolBethanidine may increase the hypotensive activities of Carvedilol.
CeliprololBethanidine may increase the hypotensive activities of Celiprolol.
ChlorothiazideBethanidine may increase the hypotensive activities of Chlorothiazide.
ChlorthalidoneBethanidine may increase the hypotensive activities of Chlorthalidone.
CilazaprilBethanidine may increase the hypotensive activities of Cilazapril.
ClomipramineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Clomipramine.
ClonidineBethanidine may increase the hypotensive activities of Clonidine.
CryptenamineBethanidine may increase the hypotensive activities of Cryptenamine.
CyclobenzaprineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Cyclobenzaprine.
CyclothiazideBethanidine may increase the hypotensive activities of Cyclothiazide.
DebrisoquinBethanidine may increase the hypotensive activities of Debrisoquin.
DeserpidineBethanidine may increase the hypotensive activities of Deserpidine.
DesipramineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Desipramine.
DesvenlafaxineDesvenlafaxine may decrease the antihypertensive activities of Bethanidine.
DiazoxideDiazoxide may increase the hypotensive activities of Bethanidine.
DiltiazemBethanidine may increase the hypotensive activities of Diltiazem.
DorzolamideBethanidine may increase the hypotensive activities of Dorzolamide.
DosulepinThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Dosulepin.
DoxazosinBethanidine may increase the hypotensive activities of Doxazosin.
DoxepinThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Doxepin.
DuloxetineDuloxetine may decrease the antihypertensive activities of Bethanidine.
EfonidipineBethanidine may increase the hypotensive activities of Efonidipine.
EnalaprilBethanidine may increase the hypotensive activities of Enalapril.
EnalaprilatBethanidine may increase the hypotensive activities of Enalaprilat.
EpoprostenolBethanidine may increase the hypotensive activities of Epoprostenol.
EprosartanBethanidine may increase the hypotensive activities of Eprosartan.
EsmirtazapineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Esmirtazapine.
EsmololBethanidine may increase the atrioventricular blocking (AV block) activities of Esmolol.
FelodipineBethanidine may increase the hypotensive activities of Felodipine.
FenoldopamBethanidine may increase the hypotensive activities of Fenoldopam.
FosinoprilBethanidine may increase the hypotensive activities of Fosinopril.
FurazolidoneFurazolidone may increase the hypotensive activities of Bethanidine.
GuanabenzBethanidine may increase the hypotensive activities of Guanabenz.
GuanadrelBethanidine may increase the hypotensive activities of Guanadrel.
GuanethidineBethanidine may increase the hypotensive activities of Guanethidine.
GuanfacineBethanidine may increase the hypotensive activities of Guanfacine.
HexamethoniumBethanidine may increase the hypotensive activities of Hexamethonium.
HydracarbazineHydracarbazine may increase the hypotensive activities of Bethanidine.
HydralazineBethanidine may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideBethanidine may increase the hypotensive activities of Hydrochlorothiazide.
HydroflumethiazideBethanidine may increase the hypotensive activities of Hydroflumethiazide.
IloprostIloprost may increase the hypotensive activities of Bethanidine.
ImipramineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Imipramine.
IndapamideBethanidine may increase the hypotensive activities of Indapamide.
IndenololBethanidine may increase the hypotensive activities of Indenolol.
IndoraminBethanidine may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Bethanidine.
IproniazidIproniazid may increase the hypotensive activities of Bethanidine.
IrbesartanBethanidine may increase the hypotensive activities of Irbesartan.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Bethanidine.
IsradipineBethanidine may increase the hypotensive activities of Isradipine.
LabetalolBethanidine may increase the hypotensive activities of Labetalol.
LacidipineBethanidine may increase the hypotensive activities of Lacidipine.
LatanoprostBethanidine may increase the hypotensive activities of Latanoprost.
LercanidipineBethanidine may increase the hypotensive activities of Lercanidipine.
LevomilnacipranLevomilnacipran may decrease the antihypertensive activities of Bethanidine.
LisinoprilBethanidine may increase the hypotensive activities of Lisinopril.
LofexidineBethanidine may increase the hypotensive activities of Lofexidine.
LosartanBethanidine may increase the hypotensive activities of Losartan.
MacitentanBethanidine may increase the hypotensive activities of Macitentan.
ManidipineBethanidine may increase the hypotensive activities of Manidipine.
MebanazineMebanazine may increase the hypotensive activities of Bethanidine.
MecamylamineBethanidine may increase the hypotensive activities of Mecamylamine.
MethyldopaBethanidine may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Bethanidine.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Bethanidine.
MetipranololBethanidine may increase the hypotensive activities of Metipranolol.
MetolazoneBethanidine may increase the hypotensive activities of Metolazone.
MetoprololBethanidine may increase the hypotensive activities of Metoprolol.
MianserinThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Mianserin.
MibefradilBethanidine may increase the hypotensive activities of Mibefradil.
MilnacipranMilnacipran may decrease the antihypertensive activities of Bethanidine.
MinaprineMinaprine may increase the hypotensive activities of Bethanidine.
MinoxidilBethanidine may increase the hypotensive activities of Minoxidil.
MirtazapineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Mirtazapine.
MoclobemideMoclobemide may increase the hypotensive activities of Bethanidine.
MoexiprilBethanidine may increase the hypotensive activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Bethanidine.
MoxonidineBethanidine may increase the hypotensive activities of Moxonidine.
NadololBethanidine may increase the hypotensive activities of Nadolol.
NebivololBethanidine may increase the hypotensive activities of Nebivolol.
NialamideNialamide may increase the hypotensive activities of Bethanidine.
NicardipineBethanidine may increase the hypotensive activities of Nicardipine.
NicorandilBethanidine may increase the hypotensive activities of Nicorandil.
NiguldipineBethanidine may increase the hypotensive activities of Niguldipine.
NilvadipineBethanidine may increase the hypotensive activities of Nilvadipine.
NimodipineBethanidine may increase the hypotensive activities of Nimodipine.
NisoldipineBethanidine may increase the hypotensive activities of Nisoldipine.
NitrendipineBethanidine may increase the hypotensive activities of Nitrendipine.
NitroprussideBethanidine may increase the hypotensive activities of Nitroprusside.
NortriptylineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Nortriptyline.
ObinutuzumabBethanidine may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Bethanidine.
OlmesartanBethanidine may increase the hypotensive activities of Olmesartan.
OmapatrilatBethanidine may increase the hypotensive activities of Omapatrilat.
OxprenololBethanidine may increase the hypotensive activities of Oxprenolol.
PargylineBethanidine may increase the hypotensive activities of Pargyline.
PenbutololBethanidine may increase the hypotensive activities of Penbutolol.
PentoliniumBethanidine may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Bethanidine.
PerindoprilBethanidine may increase the hypotensive activities of Perindopril.
PhenelzinePhenelzine may increase the hypotensive activities of Bethanidine.
PheniprazinePheniprazine may increase the hypotensive activities of Bethanidine.
PhenoxybenzamineBethanidine may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Bethanidine.
PhentolamineBethanidine may increase the hypotensive activities of Phentolamine.
PinacidilBethanidine may increase the hypotensive activities of Pinacidil.
PindololBethanidine may increase the hypotensive activities of Pindolol.
PirlindolePirlindole may increase the hypotensive activities of Bethanidine.
PivhydrazinePivhydrazine may increase the hypotensive activities of Bethanidine.
PolythiazideBethanidine may increase the hypotensive activities of Polythiazide.
PractololBethanidine may increase the atrioventricular blocking (AV block) activities of Practolol.
PrazosinBethanidine may increase the hypotensive activities of Prazosin.
PropranololBethanidine may increase the hypotensive activities of Propranolol.
ProtriptylineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Protriptyline.
QuinaprilBethanidine may increase the hypotensive activities of Quinapril.
QuinineQuinine may increase the hypotensive activities of Bethanidine.
RamiprilRamipril may increase the hypotensive activities of Bethanidine.
RasagilineRasagiline may increase the hypotensive activities of Bethanidine.
RemikirenRemikiren may increase the hypotensive activities of Bethanidine.
RescinnamineBethanidine may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Bethanidine.
RiociguatBethanidine may increase the hypotensive activities of Riociguat.
RituximabBethanidine may increase the hypotensive activities of Rituximab.
SafrazineSafrazine may increase the hypotensive activities of Bethanidine.
SaprisartanBethanidine may increase the hypotensive activities of Saprisartan.
SelegilineSelegiline may increase the hypotensive activities of Bethanidine.
SelexipagBethanidine may increase the hypotensive activities of Selexipag.
SildenafilSildenafil may increase the antihypertensive activities of Bethanidine.
SitaxentanBethanidine may increase the hypotensive activities of Sitaxentan.
SotalolBethanidine may increase the atrioventricular blocking (AV block) activities of Sotalol.
SpiraprilBethanidine may increase the hypotensive activities of Spirapril.
TadalafilTadalafil may increase the antihypertensive activities of Bethanidine.
TelmisartanBethanidine may increase the hypotensive activities of Telmisartan.
TemocaprilBethanidine may increase the hypotensive activities of Temocapril.
TerlipressinBethanidine may increase the hypotensive activities of Terlipressin.
TianeptineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Tianeptine.
TiboloneBethanidine may increase the hypotensive activities of Tibolone.
TicrynafenBethanidine may increase the hypotensive activities of Ticrynafen.
TimololBethanidine may increase the hypotensive activities of Timolol.
TolazolineBethanidine may increase the hypotensive activities of Tolazoline.
ToloxatoneToloxatone may increase the hypotensive activities of Bethanidine.
TorasemideTorasemide may increase the hypotensive activities of Bethanidine.
TrandolaprilBethanidine may increase the hypotensive activities of Trandolapril.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bethanidine.
TranylcypromineTranylcypromine may increase the hypotensive activities of Bethanidine.
TravoprostBethanidine may increase the hypotensive activities of Travoprost.
TreprostinilBethanidine may increase the hypotensive activities of Treprostinil.
TrichlormethiazideBethanidine may increase the hypotensive activities of Trichlormethiazide.
TrimazosinBethanidine may increase the hypotensive activities of Trimazosin.
TrimethaphanBethanidine may increase the hypotensive activities of Trimethaphan.
TrimipramineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Trimipramine.
UdenafilUdenafil may increase the antihypertensive activities of Bethanidine.
UnoprostoneBethanidine may increase the hypotensive activities of Unoprostone.
ValsartanValsartan may increase the hypotensive activities of Bethanidine.
VardenafilVardenafil may increase the antihypertensive activities of Bethanidine.
VenlafaxineVenlafaxine may decrease the antihypertensive activities of Bethanidine.
XylometazolineBethanidine may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Bethanidine.
Food InteractionsNot Available

Targets

Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol.
Components:
NameUniProt IDDetails
Alpha-2A adrenergic receptorP08913 Details
Alpha-2B adrenergic receptorP18089 Details
Alpha-2C adrenergic receptorP18825 Details
References
  1. Noshiro T, Miura Y, Kimura S, Meguro Y, Sugawara T, Ohashi H, Takahashi M, Sano N, Watanabe H, Ohzeki T, et al.: Functional relationships between platelet alpha 2-adrenoceptors and sympathetic nerve activity in clinical hypertensive states. J Hypertens. 1990 Dec;8(12):1097-104. [PubMed:1962798 ]
  2. Noshiro T, Miura Y, Kimura S, Meguro Y, Sugawara T, Ohashi H, Takahashi M, Sano N, Watanabe H, Ohzeki T, et al.: Functional relationship between platelet alpha 2-adrenoceptors and sympathetic nerve activity in man. Clin Exp Hypertens A. 1989;11 Suppl 1:287-94. [PubMed:2545383 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Phosphatidylinositol-4,5-bisphosphate binding
Specific Function:
In the kidney, probably plays a major role in potassium homeostasis. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive vol...
Gene Name:
KCNJ1
Uniprot ID:
P48048
Molecular Weight:
44794.6 Da
References
  1. Bkaily G, Caille JP, Payet MD, Peyrow M, Sauve R, Renaud JF, Sperelakis N: Bethanidine increases one type of potassium current and relaxes aortic muscle. Can J Physiol Pharmacol. 1988 Jun;66(6):731-6. [PubMed:3167688 ]
  2. Bkaily G: Bethanidine, nitroprusside and atrial natriuretic factor open a cGMP-sensitive K+ channel in aortic muscle. Prog Clin Biol Res. 1990;327:507-15. [PubMed:2157221 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Components:
NameUniProt IDDetails
Beta-1 adrenergic receptorP08588 Details
Beta-2 adrenergic receptorP07550 Details
Beta-3 adrenergic receptorP13945 Details
References
  1. Hart GR, Anderson RJ: Withdrawal syndromes and the cessation of antihypertensive therapy. Arch Intern Med. 1981 Aug;141(9):1125-7. [PubMed:6114720 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. Bacaner MB, Benditt DG: Antiarrhythmic, antifibrillatory, and hemodynamic actions of bethanidine sulfate: an orally effective analog of bretylium for suppression of ventricular tachyarrhythmias. Am J Cardiol. 1982 Oct;50(4):728-34. [PubMed:6812406 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23